European Lead Factory

from Wikipedia, the free encyclopedia

The European Lead Factory is a public-private partnership whose aim is to accelerate the process of pharmaceutical research in Europe. The pan-European consortium consists of seven pharmaceutical companies, academic institutions and small and medium-sized companies . The European Lead Factory is financed by the Innovative Medicines Initiative (IMI) and is IMI's largest single project. The project is an example of how open innovation in drug discovery can work in practice.

This article or section needs to be revised. Details should be given on the talk page. Please help to improve it , and then remove this flag.

The two main elements of the European Lead Factory, which has existed since 2013, are the Joint European Compound Library and the European Screening Center. Together, they offer scientists in Europe an opportunity to identify approaches for drug development by combining innovative drug targets with high-quality chemical compounds . The results are collected in a hit list: a number of compounds with affinity for the target molecule. These compounds can be used as experimental tools for research into biological processes or as a starting point for further development of new drug leads. The substances on the hit list can be optimized outside of the European Lead Factory with regard to their affinity and other properties relevant for drugs such as selectivity, solubility and metabolism. The ultimate goal is to make these active ingredients available for the treatment of previously unaddressed medical needs after their regulatory approval.

Open innovation

The Joint European Compound Library consists of a collection of around 500,000 chemical compounds. The compounds come partly from the private databases of the pharmaceutical companies and are supplemented by the new molecules that are synthesized by the chemical partners of the European Lead Factory. European researchers from academic institutions as well as small and medium-sized companies and patient organizations can submit their biological targets for screening against this collection. The screening is carried out by scientists from the European Lead Factory according to industrial standards as high-throughput screening.

Web links

Individual evidence

  1. ↑ Anna Karawajczyk, Kristina M. Orrling, De Vlieger, Jon S. B, Ton Rijnders: The European Lead Factory: A Blueprint for Public – Private Partnerships in Early Drug Discovery . In: Frontiers in Medicine . tape 3 , 2017, ISSN  2296-858X , doi : 10.3389 / fmed.2016.00075 , PMID 28154815 , PMC 5243859 (free full text).
  2. ↑ European Substance Library saves time and money in drug research in de.euronews.com. December 28, 2016. Retrieved May 17, 2017 .
  3. ^ Hugh Laverty, Kristina Maria Orrling, Fabrizio Giordanetto, Magali Poinot, Eckhard Ottow: The European lead factory — an experiment in collaborative drug discovery . In: Journal of Medicines Development Sciences . tape 1 , no. 1 , November 17, 2016, p. 20–33 ( whioce.com [accessed May 17, 2017]).
  4. ^ Katie Kingwell: European Lead Factory hits its stride . In: Nature Reviews Drug Discovery . tape 15 , no. 4 , April 1, 2016, ISSN  1474-1776 , p. 221–222 , doi : 10.1038 / nrd.2016.64 ( nature.com [accessed May 17, 2017]).
  5. ^ Philip Jones, Stuart McElroy, Angus Morrison, Andrew Pannifer: The importance of triaging in determining the quality of output from high-throughput screening . In: Future Medicinal Chemistry . tape 7 , no. 14 , September 1, 2015, ISSN  1756-8919 , p. 1847-1852 , doi : 10.4155 / fmc.15.121 .
  6. Jump up ↑ Jérémy Besnard, Philip S. Jones, Andrew L. Hopkins, Andrew D. Pannifer: The Joint European Compound Library: boosting precompetitive research . In: Drug Discovery Today . tape 20 , no. 2 , February 1, 2015, p. 181–186 , doi : 10.1016 / j.drudis.2014.08.014 ( sciencedirect.com [accessed May 17, 2017]).
  7. ↑ Anna Karawajczyk, Fabrizio Giordanetto, Jorg Benningshof, Daniel Hamza, Tuomo Kalliokoski: Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective . In: Drug Discovery Today . tape 20 , no. 11 , November 1, 2015, p. 1310-1316 , doi : 10.1016 / j.drudis.2015.09.009 ( sciencedirect.com [accessed May 17, 2017]).